SOURCE: Spencer Pharmaceutical, Inc.

November 10, 2010 15:31 ET

Spencer Pharmaceutical Hires Strategema Capital to Advise on All-Cash Buyout Offer

BOSTON, MA--(Marketwire - November 10, 2010) - Spencer Pharmaceutical Inc. (PINKSHEETS: SPPH) announced today that it has hired the services of Strategema Capital of Geneva, Switzerland to advise on the recently announced unsolicited all-cash offer.

According to the company, Strategema Capital is a boutique financial consultancy and research company who will assist the company with the buyout offer. 

"The experienced staff at Strategema will provide us the necessary assistance in dealing with this all-cash buyout offer," said Dr. Max Arella, President of Spencer Pharmaceutical Inc. "Both the size of this transaction and the complexity requires a group like Strategema to help us get this transaction to a successful completion in a short timeframe," further added Dr. Arella.

About Spencer Pharmaceutical Inc.
Spencer Pharmaceutical Inc. is a US-based Pharmaceutical Research and Development Corporation, which is developing innovative drug release and absorption systems for the treatment of metabolic diseases such as diabetes and metabolic syndrome.

Important Information About Forward-Looking Statements in this press release may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "estimate," "expect," "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above. In addition, such statements could be affected by risks and uncertainties related to the exploration for and development of mineralized material, product demand, market and customer acceptance, competition, pricing and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions. Any forward-looking statements speak only as of the date on which they are made, and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Company's website does not constitute a part of this release.

Contact Information

  • Contact:
    Dr. Max Arella
    Spencer Pharmaceutical Inc.
    Tel. 1+(617) 973-5017